A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression

Summary

The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD). This will be assessed by the change from baseline in the Hamilton depression rating scale (HAM-D; 17-item) total score from Day 1 (baseline) to the end of the 4-week treatment phase (Day 28).

Timeline

Start

2025-06-09

Primary completion

2027-06-25

Completion

2027-06-25

Drugs

Indications